Literature DB >> 1921483

Effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease.

V E Torres1, D M Wilson, J C Burnett, C M Johnson, K P Offord.   

Abstract

We compared the tubular transport of sodium and the erythrocyte sodium-lithium countertransport activity in hypertensive patients with autosomal dominant polycystic kidney disease (ADPKD) and in normotensive control subjects. In addition, we assessed the effects of inhibition of converting enzyme on renal hemodynamics and sodium excretion in hypertensive patients with ADPKD to provide information on mechanisms responsible for the increased renal vascular resistance and filtration fraction and the adjustment of the pressure-natriuresis relationship during saline expansion, observed in patients with ADPKD, hypertension, and preserved renal function. In comparison with normotensive control subjects, the hypertensive patients with ADPKD had lower renal plasma flows, higher renal vascular resistances and filtration fractions, and similar proximal and distal fractional reabsorptions of sodium. The administration of enalapril resulted in significant increases in the renal plasma flow and significant reductions in mean arterial pressure, renal vascular resistance, and filtration fraction, but the glomerular filtration rate remained unchanged. Despite the significant reduction in mean arterial pressure during inhibition of converting enzyme, the distal fractional reabsorption of sodium decreased while the total fractional excretion of sodium remained unchanged or increased slightly. No significant differences were detected between the normotensive control subjects and the hypertensive patients with ADPKD in erythrocyte sodium-lithium countertransport activity, plasma renin activity, plasma aldosterone concentration, or atrial natriuretic factor. These results suggest that the renal renin-angiotensin system plays a central role in the alterations in renal hemodynamics and sodium management associated with the development of hypertension in ADPKD.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1921483     DOI: 10.1016/s0025-6196(12)61724-8

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  14 in total

1.  Angiotensin blockade in late autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Kaleab Z Abebe; Arlene B Chapman; Robert W Schrier; William E Braun; Theodore I Steinman; Franz T Winklhofer; Godela Brosnahan; Peter G Czarnecki; Marie C Hogan; Dana C Miskulin; Frederic F Rahbari-Oskoui; Jared J Grantham; Peter C Harris; Michael F Flessner; Charity G Moore; Ronald D Perrone
Journal:  N Engl J Med       Date:  2014-11-15       Impact factor: 91.245

2.  Blood pressure in early autosomal dominant polycystic kidney disease.

Authors:  Robert W Schrier; Kaleab Z Abebe; Ronald D Perrone; Vicente E Torres; William E Braun; Theodore I Steinman; Franz T Winklhofer; Godela Brosnahan; Peter G Czarnecki; Marie C Hogan; Dana C Miskulin; Frederic F Rahbari-Oskoui; Jared J Grantham; Peter C Harris; Michael F Flessner; Kyongtae T Bae; Charity G Moore; Arlene B Chapman
Journal:  N Engl J Med       Date:  2014-11-15       Impact factor: 91.245

Review 3.  Potential pharmacological interventions in polycystic kidney disease.

Authors:  Amirali Masoumi; Berenice Reed-Gitomer; Catherine Kelleher; Robert W Schrier
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 4.  Polycystic kidney disease--a truly pediatric problem.

Authors:  M R Ogborn
Journal:  Pediatr Nephrol       Date:  1994-12       Impact factor: 3.714

Review 5.  Hypertension in autosomal dominant polycystic kidney disease.

Authors:  Arlene B Chapman; Konrad Stepniakowski; Frederic Rahbari-Oskoui
Journal:  Adv Chronic Kidney Dis       Date:  2010-03       Impact factor: 3.620

6.  Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Kaleab Z Abebe; Robert W Schrier; Ronald D Perrone; Arlene B Chapman; Alan S Yu; William E Braun; Theodore I Steinman; Godela Brosnahan; Marie C Hogan; Frederic F Rahbari; Jared J Grantham; Kyongtae T Bae; Charity G Moore; Michael F Flessner
Journal:  Kidney Int       Date:  2016-12-16       Impact factor: 10.612

7.  Urinary angiotensinogen level is associated with potassium homeostasis and clinical outcome in patients with polycystic kidney disease: a prospective cohort study.

Authors:  Hyoungnae Kim; Seohyun Park; Jong Hyun Jhee; Hae-Ryong Yun; Jung Tak Park; Seung Hyeok Han; Joongyub Lee; Soo Wan Kim; Yeong Hoon Kim; Yun Kyu Oh; Shin-Wook Kang; Kyu Hun Choi; Tae-Hyun Yoo
Journal:  BMC Nephrol       Date:  2019-03-25       Impact factor: 2.388

8.  The HALT polycystic kidney disease trials: design and implementation.

Authors:  Arlene B Chapman; Vicente E Torres; Ronald D Perrone; Theodore I Steinman; Kyongtae T Bae; J Philip Miller; Dana C Miskulin; Frederic Rahbari Oskoui; Amirali Masoumi; Marie C Hogan; Franz T Winklhofer; William Braun; Paul A Thompson; Catherine M Meyers; Cass Kelleher; Robert W Schrier
Journal:  Clin J Am Soc Nephrol       Date:  2010-01       Impact factor: 8.237

Review 9.  Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease.

Authors:  Tevfik Ecder; Robert W Schrier
Journal:  Nat Rev Nephrol       Date:  2009-04       Impact factor: 28.314

Review 10.  Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease.

Authors:  Fouad T Chebib; Vicente E Torres
Journal:  Clin J Am Soc Nephrol       Date:  2018-07-26       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.